Cognition Therapeutics Inc
NASDAQ:CGTX
Cognition Therapeutics Inc
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
You don't have any saved screeners yet
